Blueprint Genetics
Helsinki
About Blueprint Genetics
Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $26.3M
- Funding stage: M&A
- Last round: Debt Financing (Sep 2020)
- Website: blueprintgenetics.com
- Phone: +358 40 2511372
Industries & Categories
Biotechnology, Genetics, Health Care, Health Diagnostics, Hospital
Social Profiles
Canonical: https://fsome.com/organization/blueprint-genetics-131048 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.